The gut and intestinal bacteria in chronic heart failure

Current Drug Metabolism

Volumn 10, Issue 1, 2009, Pages 22-28

  Sandek, Anja ^a   Anker, Stefan D ^a   von Haehling, Stephan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antibodies; Cachexia; Chronic heart failure; Cytokines; Gut; Inflammation; Intestinal dysfunction

Indexed keywords

ALKALINE PHOSPHATASE; BACTERIUM LIPOPOLYSACCHARIDE; BILIRUBIN; CD14 ANTIGEN; ENDOTOXIN; ERYTHROPOIETIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; HEPCIDIN; IMMUNOGLOBULIN A; INTERLEUKIN 1; INTERLEUKIN 6; STEROID HORMONE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; CACHEXIA; CATABOLISM; CATECHOLAMINE RELEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DYSPNEA; ERYTHROID PRECURSOR CELL; EXERCISE TOLERANCE; FATIGUE; FERRITIN BLOOD LEVEL; HEART DISEASE; HEART FAILURE; HOMEOSTASIS; HORMONE RELEASE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; IRON ABSORPTION; IRON BALANCE; IRON DEFICIENCY ANEMIA; LIVER DYSFUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PERIPHERAL ISCHEMIA; REVIEW; SIGNAL TRANSDUCTION; STEROID ANALYSIS; STEROID BLOOD LEVEL; STEROID METABOLISM; ANIMAL; CHRONIC DISEASE; INTESTINE; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; MICROCIRCULATION;

ANIMALS; CACHEXIA; CHRONIC DISEASE; CYTOKINES; HEART FAILURE; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; INTESTINES; MICROCIRCULATION;

EID: 62749167937     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009787048374     Document Type: Review

References (91)

1. Von Haehling, S.; Doehner W.; Anker, S.D. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res., 2007, 73(2), 298-309.
2. Anker, S.D.; Egerer, K.R.; Volk, H.D.; Kox, W.J.; Poole-Wilson, P.A.; Coats, A.J. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am. J. Cardiol., 1997, 79(19), 1426-1430.
3. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H.M.; Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med., 1990, 323(4), 236-241.
4. Von Haehling, S.; Jankowska, E.A.; Morgenthaler, N.G.; Vassanelli, C.; Zanolla, L.; Rozentryt, P.; Filippatos, G.S.; Doehner, W.; Koehler, F.; Papassotiriou, J.; Kremastinos, D.T.; Banasiak, W.; Struck, J.; Ponikowski, P.; Bergmann, A.; Anker, S.D. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J. Am. Coll. Cardiol., 2007, 50(20), 1973-1980.
5. Lainscak, M.; von Haehling, S.; Springer, J.; Anker, S.D. Biomarkers for chronic heart failure. Heart Fail. Monit., 2007, 5(3), 77-82.
6. Ferrari, R.; Bachetti, T.; Confortini, R.; Opasich, C.; Febo, O.; Corti, A.; Cassani, G.; Visioli, O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation, 1999, 92(6), 1479-1486.
7. Rauchhaus, M.; Doehner, W.; Francis, D.P.; Davos, C.; Kemp, M.; Liebenthal, C.; Niebauer, J.; Hooper, J.; Volk, H.D.; Coats, A.J.; Anker, S.D. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation, 2000, 102(25), 3060-3067.
8. Deswal, A.; Petersen, N.J.; Feldman, A.M.; Young, J.B.; White, B.G.; Mann, D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation, 2001, 103(16), 2055-2059.
9. Von Haehling, S.; Jankowska, E.A.; Anker, S.D. Tumour necrosis factor-alpha and the failing heart - pathophysiology and therapeutic implications. Basic Res. Cardiol., 2004, 99(1), 18-28.
10. Cain, B.S.; Meldrum, D.R.; Dinarello, C.A.; Meng, X.; Joo, K.S.; Banerjee, A.; Harken, A.H. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit. Care Med., 1999, 27(7), 1309-1318.
11. Kumar, A.; Haery, C.; Parrillo, J.E. Myocardial dysfunction in septic shock. Crit. Care Clin., 2000, 16(2), 251-287.
12. Müller-Werdan, U.; Engelmann, H.; Werdan, K. Cardiodepression by tumor necrosis factor-alpha. Eur. Cytokine Netw., 1998, 9(4), 689-91.
13. Parker, M.M. Pathophysiology of cardiovascular dysfunction in septic shock. New Horiz., 1998, 6(2):130-138.
14. Anker, S.D.; von Haehling, S. Inflammatory mediators in chronic heart failure: an overview. Heart, 2004, 90(4), 464-470.
15. Gao, C.Q.; Sawicki, G.; Suarez-Pinzon, W.L.; Csont, T.; Wozniak, M.; Ferdinandy, P.; Schulz, R. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc. Res., 2003, 57(2), 426-433.
16. Meldrum, D.R. Tumor necrosis factor in the heart. Am. J. Physiol., 1998, 274, R577-R595.
17. Yokoyama, T.; Nakano, M.; Bednarczyk, J.L.; McIntyre, B.W.; Entman, M.; Mann, D.L. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation, 1997, 95(5), 1247-1252.
18. Krown, K.A.; Page, M.T.; Nguyen, C.; Zechner, D.; Gutierrez, V.; Comstock, K.L.; Glembotski, C.C.; Quintana, P.J.; Sabbadini, R.A. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest., 1996, 98(12), 2854-2865.
19. Rauchhaus, M.; Müller-Werdan, U. Cytokines in heart diseases. Internist, 2001, 42(1), 75-84.
20. Shan, K.; Kurrelmeyer, K.; Seta, Y.; Wang, F.; Dibbs, Z.; Deswal, A.; Lee-Jackson, D.; Mann, D.L. The role of cytokines in disease progression in heart failure. Curr. Opin. Cardiol., 1997, 12(3), 218-223.
21. Devaux, B.; Scholz, D.; Hirche, A.; Klövekorn, W.P.; Schaper, J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur. Heart J., 1997, 18(3), 470-479.
22. Hasper, D.; Hummel, M.; Kleber, F.X.; Reindl, I.; Volk, H.D. Systemic inflammation in patients with heart failure. Eur. Heart J., 1998, 19(5), 761-765.
23. Müller-Werdan, U. and Werdan, K. Immune modulation by catecholamines - a potential mechanism of cytokine release in heart failure? Herz, 2000, 25(3), 271-273.
24. Jankowska, E.A.; Ponikowski, P.; Piepoli, M.F.; Banasiak, W.; Anker, S.D.; Poole-Wilson, P.A. Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. Cardiovasc. Res., 2006, 70(3), 434-445.
25. Sharma, R.; Bolger, A.P.; Rauchhaus, M.; von Haehling, S.; Doehner, W.; Adcock, I.M.; Barnes, P.J.; Poole-Wilson, P.A.; Volk, H.D.; Coats, A.J.; Lim, S.; Anker, S.D. Cellular endotoxin desensitization in patients with severe chronic heart failure. Eur. J. Heart Fail., 2005, 7(5), 865-868.
26. Genth-Zotz, S.; von Haehling, S.; Bolger, A.P.; Kalra, P.R.; Wensel, R.; Coats, A.J.; Anker, S.D. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am. J. Cardiol., 2002, 90(11), 1226-1230.
27. Koloczek V, Rauchhaus M, Crane R. Markers of intestinal ischaemia relate to immune activation in chronic heart failure. Circulation, 1999; 100(Suppl), I-206.
28. Sandek, A.; Bauditz, J.; Swidsinski, A.; Buhner, S.; Weber-Eibel, J.; von Haehling, S.; Schroedl, W.; Karhausen, T.; Doehner, W.; Rauchhaus, M.; Poole-Wilson, P.A.; Volk, H.D.; Lochs, H.; Anker, S.D. Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol., 2007, 50(16), 1561-1569.
29. Peschel, T.; Schonauer, M.; Thiele, H.; Anker, S.D.; Schuler, G.; Niebauer, J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur. J. Heart Fail., 2003, 5(5), 609-614.
30. Doehner, W.; Schoene, N.; Rauchhaus, M.; Leyva-Leon, F.; Pavitt, D.V.; Reaveley, D.A.; Schuler, G.; Coats, A.J.; Anker, S.D.; Hambrecht, R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation, 2002, 105(22), 2619-2624.
31. Vanderheyden, M.; Kersschot, E.; Paulus, W.J. Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure. Eur. Heart J., 1998, 19(5), 747-752.
32. Anker, S.D.; Volterrani, M.; Egerer, K.R.; Felton, C.V.; Kox, W.J.; Poole-Wilson, P.A.; Coats, A.J. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM, 1998, 91(3), 199-203.
33. Meyer, F.J.; Borst, M.M.; Zugck, C.; Kirschke, A.; Schellberg, D.; Kübler, W; Haass, M. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation, 2001, 103(17), 2153-2158.
34. Chiappa, G.R.; Roseguini, B.T.; Vieira, P.J.; Alves, C.N.; Tavares, A.; Winkelmann, E.R.; Ferlin, E.L.; Stein, R.; Ribeiro, J.P. Inspiratory muscle training improves blood flow to resting and exercising limbs in patients with chronic heart failure. J. Am. Coll. Cardiol., 2008, 51(17), 1663-71.
35. Hussain, S.N.; Chatillon, A.; Comtois, A. ; Roussos, C.; Magder, S. Chemical activation of thin-fiber phrenic afferents. 2. Cardiovascular responses. J. Appl. Physiol., 1991, 70(1), 77-86.
36. Krack, A.; Richartz, B.M.; Gastmann, A.; Greim, K.; Lotze, U.; Anker, S.D.; Figulla, H.R. Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. Eur. J. Heart Fail., 2004, 6(4), 403-407.
37. Gutierrez, G.; Palizas, F.; Doglio, G.; Wainsztein, N.; Gallesio, A.; Pacin, J.; Dubin, A.; Schiavi, E.; Jorge, M.; Pusajo, J.; Klein, F.; San Roman, E.; Dorfmann, B.; Shottlender, J.; Giniger, R. Gastric intramucosal pH as a therapeutic index of tissue oxygination in critically ill patients. Lancet, 1992, 339(8787), 195-199.
38. Maynard, N.; Bihari, D.; Beale, R.; Smithies, M.; Baldock, G.; Mason, R.; McColl, I. Assessmant of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. JAMA, 1993, 270(10), 1203-1210.
39. Takala J. Determinants of splanchnic blood flow. Br. J. Anaesth., 1997, 77(1), 50-58.
40. Boyd, O.; Mackay, C.; Lamb, G.; Bland, J.M.; Grounds, R.M.; Bennett, E.D. Comparison of clinical information gained from routine blood-gas analysis and from gastric tonometry for intramural pH. Lancet, 1993, 341(8838), 142-146.
41. Bruewer, M.; Luegering, A.; Kucharzik, T.; Parkos, C.A.; Madara, J.L.; Hopkins, A.M.; Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol., 2003, 171(11), 6164-6172.
42. Genth-Zotz, S.; von Haehling, S.; Bolger, A.P.; Kalra, P.R.; Wensel, R.; Coats, A.J.; Volk, H.D.; Anker, S.D. The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure. Eur. J. Heart Fail., 2006, 8(4), 366-372.
43. Földes, G.; von Haehling, S.; Anker, S.D. Toll-like receptor modulation in cardiovascular disease: a target for intervention? Expert Opin. Investig. Drugs, 2006, 15(8), 857-871.
44. Földes, G.; von Haehling, S.; Okonko, D.O.; Jankowska, E.A.; Poole-Wilson, P.A.; Anker, S.D. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int. J. Cardiol., 2008, 124(1), 80-85.
45. Flierl, M.A.; Rittirsch, D.; Nadeau, B.A.; Chen; A.J.; Sarma, J.V.; Zetoune, F.S.; McGuire, S.R.; List, R.P.; Day, D.E.; Hoesel, L.M.; Gao, H.; Van Rooijen, N.; Huber-Lang, M.S.; Neubig, R.R.; Ward, P.A. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature, 2007, 449(7163), 721-725.
46. Von Haehling, S.; Genth-Zotz, S.; Bolger, A.P.; Kalra, P.R.; Kemp, M.; Adcock, I.M.; Poole-Wilson, P.A.; Dietz, R.; Anker, S.D. Effect of noradrenaline and isoproterenol on lipopolysaccharide-induced tumor necrosis factor-alpha production in whole blood from patients with chronic heart failure and the role of beta-adrenergic receptors. Am. J. Cardiol., 2005, 95(7), 885-889.
47. Sandek, A.; Utchill, S.; Rauchhaus, M. The endotoxin-lipoprotein hypothesis - an update. Arch. Med. Sci., 2007, 3(4a), 81-90.
48. Anker, S.D.; Ponikowski, P.P.; Clark, A.L.; Leyva, F.; Rauchhaus, M.; Kemp, M.; Teixeira, M.M.; Hellewell, P.G.; Hooper, J.; Poole-Wilson, P.A.; Coats, A.J. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur. Heart J., 1999, 20(9), 683-693.
49. Anker, S.D.; Clark, A.L.; Kemp, M.; Salsbury, C.; Teixeira, M.M.; Hellewell, P.G.; Coats, A.J. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol., 1997, 30(4), 997-1001.
50. Anker, S.D.; Chua, T.P.; Ponikowski, P.; Harrington, D.; Swan, J.W.; Kox, W.J.; Poole-Wilson, P.A.; Coats, A.J. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation, 1997, 96(2), 526-534.
51. Anker, S.D.; Ponikowski, P.; Varney, S.; Chua, T.P.; Clark, A.L.; Webb-Peploe, K.M.; Harrington, D.; Kox, W.J.; Poole-Wilson, P.A.; Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet, 1997, 349(9058), 1050-1053.
52. Springer, J.; von Haehling, S.; Anker, S.D. The need for a standardized definition for cachexia in chronic illness. Nat. Clin. Pract. Endocrinol. Metab., 2006, 2(8), 416-417.
53. Evans, W.J.; Morley, J.E.; Argilés, J.; Bales, C.; Baracos, V.; Guttridge, D.; Jatoi, A.; Kalantar-Zadeh, K.; Lochs, H.; Mantovani, G.; Marks, D.; Mitch, W.E.; Muscaritoli, M.; Najand, A.; Ponikowski, P.; Rossi Fanelli, F.; Schambelan, M.; Schols, A.; Schuster, M.; Thomas, D.; Wolfe, R.; Anker, S.D. Cachexia: A new definition. Clin. Nutr., 2008, 27(6), 793-799.
54. Adams, V.; Jiang, H.; Yu, J.; Möbius-Winkler, S.; Fiehn, E.; Linke, A.; Weigl, C; Schuler, G.; Hambrecht, R. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol., 1999, 33(4), 959-965.
55. Von Haehling, S.; Genth-Zotz, S.; Anker, S.D.; Volk, H.D. Cachexia: a therapeutic approach beyond cytokine antagonism. Int. J. Cardiol., 2002, 85(1), 173-183.
56. Langhans, W.; Hrupka, B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides, 1999, 33(5), 415-424.
57. Kirchgessner, T.G.; Uysal, K.T.; Wiesbrock, S.M.; Marino, M.W.; Hotamisligil, G.S. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J. Clin. Invest., 1997, 100(11), 2777-2782.
58. Aubert, A.; Goodall, G; Dantzer, R. Compared effects of cold ambient temperature and cytokines on macronutrient intake in rats. Physiol. Behav., 1995, 57(5), 869-873.
59. King, D.; Smith, M.L.; Chapman, T.J.; Stockdale, H.R.; Lye, M. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing, 1996, 25(2), 144-149.
60. Arutyunov, G.P.; Kostyukevich, O.I.; Serov, R.A.; Rylova, N.V.; Bylova, N.A. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int. J. Cardiol., 2008, 125(2), 240-245.
61. Evans, P.A.; Newby, T.J.; Stokes, C.R.; Patel, D.; Bourne, F.J. Antibody response of the lactating sow to oral immunization with Escherichia coli. Scand. J. Immunol., 1980, 11(4), 419-429.
62. Ludwig, K.; Grabhorn, E.; Bitzan, M.; Bobrowski, C.; Kemper, M.J.; Sobottka, I.; Laufs, R.; Karch, H.; Müller-Wiefel, D.E. Saliva IgM and IgA are a sensitive indicator of the humoral immune response to Escherichia coli O157 lipopolysaccharide in children with enteropathic hemolytic uremic syndrome. Pediatr. Res., 2002, 52(2), 307-313.
63. Mellander, L.; Carlsson, B.; Hanson, L.A. Appearance of secretory IgM and IgA antibodies to Escherichia coli in saliva during early infancy and childhood. J. Pediatr., 1984, 104(4), 564-568.
64. Kadaoui, K.A.; Corthesy, B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J. Immunol., 2007, 179(11), 7751-7757.
65. Conraads, V.M.; Jorens, P.G.; De Clerck, L.S.; Van Saene, H.K.; Ieven, M.M.; Bosmans, J.M.; Schuerwegh, A.; Bridts, C.H.; Wuyts, F.; Stevens, W.J.; Anker, S.D.; Rauchhaus, M.; Vrints, C.J. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur. J. Heart Fail., 2004, 6(4), 483-491.
66. Anker, S.D.; Clark, A.L.; Kemp, M.; Salsbury, C.; Teixeira, M.M.; Hellewell, P.G.; Coats, A.J. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol., 1997, 30(4), 997-1001.
67. Güder, G.; Bauersachs, J.; Frantz, S.; Weismann, D.; Allolio, B.; Ertl, G.; Angermann, C.E.; Störk, S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation, 2007, 115(13), 1754-1761.
68. Langman, M.J.; Cooke, A.R. Gastric and duodenal ulcer and their associated diseases. Lancet, 1976, 1(7961), 680-683.
69. Kiziltaş, S.; Imeryüz, N.; Gürcan, T.; Siva, A.; Saip, S.; Dumankar, A.; Kalayci, C.; Ulusoy, N.B. Corticosteroidtherapy augments gastroduodenal permeability to sucrose. Am. J. Gastroenterol., 1998, 93(12), 2420-2425.
70. Jankowska, E.A.; Biel, B.; Majda, J.; Szklarska, A.; Lopuszanska, M.; Medras, M.; Anker, S.D.; Banasiak, W.; Poole-Wilson, P.A.; Ponikowski, P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation, 2006, 114(17), 1829-1837.
71. Okonko, D.O. and Anker, S.D. Anemia in chronic heart failure: pathogenetic mechanisms. J. Card. Fail., 2004, 10(1 Suppl), S5-S9.
72. Szachniewicz, J.; Petruk-Kowalczyk, J.; Majda, J.; Kaczmarek, A.; Reczuch, K.; Kalra, P.R.; Piepoli, M.F.; Anker, S.D.; Banasiak, W.; Ponikowski, P. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int. J. Cardiol., 2003, 90(2-3), 303-308.
73. Ponikowski, P.; Anker, S.D.; Szachniewicz, J.; Okonko, D.; Ledwidge, M; Zymlinski, R.; Ryan, E.; Wasserman, S.M.; Baker, N.; Rosser, D.; Rosen, S.D.; Poole-Wilson, P.A.; Banasiak, W.; Coats, A.J.; McDonald, K. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol., 2007, 49(7), 753-762.
74. Nanas, J.N.; Matsouka, C.; Karageorgopoulos, D.; Leonti, A.; Tsolakis, E.; Drakos, S.G.; Tsagalou, E.P.; Maroulidis, G.D.; Alexopoulos, G.P.; Kanakakis, J.E.; Anastasiou-Nana, M.I. Etiology of anemia in patients with advanced chronic heart failure. J. Am. Coll. Cardiol., 2006, 48(12), 2485-2489.
75. Silverberg, D.S.; Wexler, D.; Laina, A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J. Nephrol., 2004, 17(6), 749-761.
76. Weiss, G.; Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med., 2005, 352(10),1011-1023.
77. Ganz, T. Hepcidin in iron metabolism. Curr. Opin. Hematol., 2004, 11(4), 251-254.
78. Zannad, F.; Alla, F.; Dousset B; Perez, A; Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation, 2000, 102(22), 2700-2706.
79. Van Lingen, R.; Warshow, U.; Dalton, H.R.; Hussaini, S.H. Jaundice as a presentation of heart failure. J. R. Soc. Med., 2005, 98(8), 357-359.
80. Dichtl, W.; Vogel, W.; Dunst, K.M.; Grander, W.; Alber, H.F.; Frick, M.; Antretter, H.; Laufer, G.; Pachinger, O.; Pölzl, G. Cardiac hepatopathy before and after heart transplantation. Transpl. Int., 2005, 18(6), 697-702.
81. Dillon, J.F.; Finlayson, N.D.C. The liver in systemic disease. 3rd. ed.; Churchill Livingstone: Edinburgh, 1997.
82. Lau, G.T.; Tan, H.C.; Kritharides, L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am. J. Cardiol., 2002, 90(12), 1405-1408.
83. Szyguła-Jurkiewicz, B.; Wojnicz, R.; Lekston, A.; Duszańska, A.; Spinczyk, B.; Nowak, J.; Niklewski, T.; Halewski, K. and Poloński, L. Effect of elevated bilirubin levels on the long-term outcome in patients with chronic heart failure due to hypertension. Pol. Arch. Med. Wewn., 2007, 117(5-6), 227-233.
84. Cogger, V.C.; Fraser, R.; Le Couteur, D.G. Liver dysfunction and heart failure. Am. J. Cardiol., 2003, 91(11), 1399.
85. Fraser, R.; Bowler, L.M.; Day, W.A.; Dobbs, B.; Johnson, H.D.; Lee, D. High perfusion pressure damages the sieving ability of sinusoidal endothelium in rat livers. Br. J. Exp. Pathol., 1980, 61(2), 222-228.
86. Niebauer, J.; Volk, H.D.; Kemp, M.; Dominguez, M.; Schumann, R.R.; Rauchhaus, M.; Poole-Wilson, P.A.; Coats, A.J.; Anker, S.D. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet, 1999, 353(9167), 1838-1842.
87. Shibayama, Y. Enhanced hepatotoxicity of endotoxin by hypoxia. Pathol. Res. Pract., 1987, 182(3), 390-395.
88. Shibayama, Y. The role of hepatic venous congestion and endotoxaemia in the production of fulminant hepatic failure secondary to congestive heart failure. J. Pathol., 1987, 151(2), 133-138.
89. Seeto, R.K.; Fenn, B.; Rockey, D.C. Ischemic hepatitis: clinical presentation and pathogenesis. Am. J. Med., 2000, 109(2), 109-113.
90. Raja, K.; Kochhar, R.; Sethy, P.K.; Dutta, U.; Bali, H.K.; Varma, J.S. An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure. Gastrointest. Endosc., 2004, 60(6), 887-893.
91. Sandek, A.; Rauchhaus, M.; Anker, S.D.; von Haehling, S. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11(5), 632-639.